Hubbry Logo
PorphyriaPorphyriaMain
Open search
Porphyria
Community hub
Porphyria
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Porphyria
Porphyria
Porphyria
View on Wikipedia
from Wikipedia

Porphyria
Left figure is urine on the first day while the right figure is urine after three days of sun exposure showing the classic change in color to purple.
Pronunciation
SpecialtyHematology, dermatology, neurology
SymptomsDepending on subtype—abdominal pain, chest pain, vomiting, confusion, constipation, fever, seizures, blisters with sunlight[1][2]
Usual onsetRecurrent attacks that last days to weeks[2]
CausesUsually genetic[2]
Diagnostic methodBlood, urine, and stool tests, genetic testing[2]
Differential diagnosisLead poisoning, alcoholic liver disease[3]
TreatmentDepends on type and symptoms[2]
Frequency1 to 100 in 50,000 people[1]

Porphyria (/pɔːrˈfɪriə/ or /pɔːrˈfaɪriə/) is a group of disorders in which substances called porphyrins build up in the body, adversely affecting the skin or nervous system.[1] The types that affect the nervous system are also known as acute porphyria, as symptoms are rapid in onset and short in duration.[1] Symptoms of an attack include abdominal pain, chest pain, vomiting, confusion, constipation, fever, high blood pressure, and high heart rate.[1][2][4] The attacks usually last for days to weeks.[2] Complications may include paralysis, low blood sodium levels, and seizures.[4] Attacks may be triggered by alcohol, smoking, hormonal changes, fasting, stress, or certain medications.[2][4] If the skin is affected, blisters or itching may occur with sunlight exposure.[2]

Most types of porphyria are inherited from one or both of a person's parents and are due to a mutation in one of the genes that make heme.[2] They may be inherited in an autosomal dominant, autosomal recessive, or X-linked dominant manner.[1] One type, porphyria cutanea tarda, may also be due to hemochromatosis (increased iron in the liver), hepatitis C, alcohol, or HIV/AIDS.[1] The underlying mechanism results in a decrease in the amount of heme produced and a build-up of substances involved in making heme.[1] Porphyrias may also be classified by whether the liver or bone marrow is affected.[1] Diagnosis is typically made by blood, urine, and stool tests.[2] Genetic testing may be done to determine the specific mutation.[2] Hepatic porphyrias are those in which the enzyme deficiency occurs in the liver. Hepatic porphyrias include acute intermittent porphyria (AIP), variegate porphyria (VP), aminolevulinic acid dehydratase deficiency porphyria (ALAD), hereditary coproporphyria (HCP), and porphyria cutanea tarda.[5]

Treatment depends on the type of porphyria and the person's symptoms.[2] Treatment of porphyria of the skin generally involves the avoidance of sunlight, while treatment for acute porphyria may involve giving intravenous heme or a glucose solution.[2] Rarely, a liver transplant may be carried out.[2]

The precise prevalence of porphyria is unclear, but it is estimated to affect between 1 and 100 per 50,000 people.[1] Rates are different around the world.[2] Porphyria cutanea tarda is believed to be the most common type.[1] The disease was described as early as 370 BC by Hippocrates.[6] The underlying mechanism was first described by German physiologist and chemist Felix Hoppe-Seyler in 1871.[6] The name porphyria is from the Greek πορφύρα, porphyra, meaning "purple", a reference to the color of the urine that may be present during an attack.[6]

Signs and symptoms

[edit]
A skin rash in a person with porphyria

Acute porphyrias

[edit]

Acute intermittent porphyria (AIP), variegate porphyria (VP), aminolevulinic acid dehydratase deficiency porphyria (ALAD) and hereditary coproporphyria (HCP). These diseases primarily affect the nervous system, resulting in episodic crises known as acute attacks. The major symptom of an acute attack is abdominal pain, often accompanied by vomiting, hypertension (elevated blood pressure), and tachycardia (an abnormally rapid heart rate).[4]

The most severe episodes may involve neurological complications: typically motor neuropathy (severe dysfunction of the peripheral nerves that innervate muscle), which leads to muscle weakness and potentially to quadriplegia (paralysis of all four limbs) and central nervous system symptoms such as seizures and coma. Occasionally, there may be short-lived psychiatric symptoms such as anxiety, confusion, hallucinations, and, very rarely, overt psychosis. All these symptoms resolve once the acute attack passes.[citation needed]

Given the many presentations and the relatively low occurrence of porphyria, patients may initially be suspected to have other, unrelated conditions. For instance, the polyneuropathy of acute porphyria may be mistaken for Guillain–Barré syndrome, and porphyria testing is commonly recommended in those situations.[7] Elevation of aminolevulinic acid from lead-induced disruption of heme synthesis results in lead poisoning having symptoms similar to acute porphyria.[8][9][10][11][12][13]

Chronic porphyrias

[edit]

The non-acute porphyrias are X-linked dominant protoporphyria (XLDPP), congenital erythropoietic porphyria (CEP), porphyria cutanea tarda (PCT), and erythropoietic protoporphyria (EPP). None of these is associated with acute attacks: their primary manifestation is with skin disease. For this reason, these four porphyrias—along with two acute porphyrias, VP and HCP, that may also involve skin manifestations—are sometimes called cutaneous porphyrias.

Skin disease is encountered where excess porphyrins accumulate in the skin. Porphyrins are photoactive molecules, and exposure to light results in promotion of electrons to higher energy levels. When these return to the resting energy level or ground state, energy is released. This accounts for the property of fluorescence typical of the porphyrins. This causes local skin damage.

Two distinct patterns of skin disease are seen in porphyria:

  • Immediate photosensitivity. This is typical of XLDPP and EPP. Following a variable period of sun exposure—typically about 30 minutes—patients complain of severe pain, burning, and discomfort in exposed areas. Typically, the effects are not visible, though occasionally there may be some redness and swelling of the skin.
  • Vesiculo-erosive skin disease. This—a reference to the characteristic blistering (vesicles) and open sores (erosions) noted in patients—is the pattern seen in CEP, PCT, VP, and HCP. The changes are noted only in sun-exposed areas such as the face and back of the hands. Milder skin disease, such as that seen in VP and HCP, consists of increased skin fragility in exposed areas with a tendency to form blisters and erosions, particularly after minor knocks or scrapes. These heal slowly, often leaving small scars that may be lighter or darker than normal skin. More severe skin disease is sometimes seen in PCT, with prominent lesions, darkening of exposed skin such as the face, and hypertrichosis: abnormal hair growth on the face, particularly the cheeks. The most severe disease is seen in CEP and a rare variant of PCT known as hepatoerythropoietic porphyria (HEP); symptoms include severe shortening of digits, loss of skin appendages such as hair and nails, and severe scarring of the skin with progressive disappearance of ears, lips, and nose. Patients may also show deformed, discolored teeth or gum and eye abnormalities.

Cause

[edit]

The porphyrias are generally considered genetic in nature.[citation needed]

Genetics

[edit]

Subtypes of porphyrias depend on which enzyme is deficient.

Porphyria type Deficient enzyme Type of porphyria Inheritance Symptoms Prevalence
Aminolevulinate dehydratase deficiency porphyria (ALADP) 5-aminolevulinate dehydratase (ALAD) Hepatic Autosomal recessive[14] Abdominal pain, neuropathy[14] Extremely rare; fewer than 10 cases ever reported.[15]
Acute intermittent porphyria (AIP) Hydroxymethylbilane synthase (HMBS) formerly porphobilinogen deaminase (PBGD) Hepatic Autosomal dominant[14] Periodic abdominal pain, peripheral neuropathy, psychiatric disorders, tachycardia[14] 1 in 10,000[16]–20,000[16]
Congenital erythropoietic porphyria (CEP) uroporphyrinogen synthase (UROS) Erythropoietic Autosomal recessive[14] Severe photosensitivity with erythema, swelling and blistering. Hemolytic anemia, splenomegaly[14] 1 in 1,000,000 or less.[17]
Porphyria cutanea tarda (PCT) uroporphyrinogen decarboxylase (UROD) Hepatic Approximately 80% sporadic,[18] 20% Autosomal dominant[14] Photosensitivity with vesicles and bullae[14] 1 in 10,000[19]
Hereditary coproporphyria (HCP) coproporphyrinogen oxidase (CPOX) Hepatic Autosomal dominant[14] Photosensitivity, neurologic symptoms, colic[14] 1 in 500,000[19]
Harderoporphyria coproporphyrinogen oxidase (CPOX) Erythropoietic Autosomal recessive[14] Jaundice, anemia, enlarged liver and spleen, often neonatal. Photosensitivity later. Extremely rare; fewer than 10 cases ever reported.
Variegate porphyria (VP) protoporphyrinogen oxidase (PPOX) Hepatic Autosomal dominant[20] Photosensitivity, neurologic symptoms, developmental delay 1 in 300 in South Africa[19]
1 in 75,000 in Finland[21]
Erythropoietic protoporphyria (EPP) ferrochelatase (FECH) Erythropoietic Autosomal recessive[14] Photosensitivity with skin lesions. Gallstones, mild liver dysfunction[14] 1 in 75,000[19]–200,000[19]

X-linked dominant protoporphyria is a rare form of erythropoietic protoporphyria caused by a gain-of-function mutation in ALAS2 characterized by severe photosensitivity.[22][23]

In the autosomal recessive types, anyone who inherit a single gene may become a carrier. Generally they do not have symptoms but may pass the gene on to offspring.[24]

Triggers

[edit]

Acute porphyria can be triggered by a number of drugs, most of which are believed to trigger it by interacting with enzymes in the liver that are made with heme. Such drugs include:[25][26][27]

Pathogenesis

[edit]
Heme synthesis. Note that some reactions occur in the cytoplasm and some in the mitochondrion (yellow).

In humans, porphyrins are the main precursors of heme, an essential constituent of hemoglobin, myoglobin, catalase, peroxidase, and P450 liver cytochromes.[28]

The body requires porphyrins to produce heme, which is used to carry oxygen in the blood among other things, but in the porphyrias there is a deficiency (inherited or acquired) of the enzymes that transform the various porphyrins into others, leading to abnormally high levels of one or more of these substances. Porphyrias are classified in two ways, by symptoms and by pathophysiology. Physiologically, porphyrias are classified as liver or erythropoietic based on the sites of accumulation of heme precursors, either in the liver or in the bone marrow and red blood cells.[29]

Deficiency in the enzymes of the porphyrin pathway leads to insufficient production of heme. Heme function plays a central role in cellular metabolism. This is not the main problem in the porphyrias; most heme synthesis enzymes—even dysfunctional enzymes—have enough residual activity to assist in heme biosynthesis. The principal problem in these deficiencies is the accumulation of porphyrins, the heme precursors, which are toxic to tissue in high concentrations. The chemical properties of these intermediates determine the location of accumulation, whether they induce photosensitivity, and whether the intermediate is excreted (in the urine or feces).[citation needed]

There are eight enzymes in the heme biosynthetic pathway, four of which—the first one and the last three—are in the mitochondria, while the other four are in the cytosol. Defects in any of these can lead to some form of porphyria. The hepatic porphyrias are characterized by acute neurological attacks (seizures, psychosis, extreme back and abdominal pain, and an acute polyneuropathy), while the erythropoietic forms present with skin problems, usually a light-sensitive blistering rash and increased hair growth. Variegate porphyria (also porphyria variegata or mixed porphyria), which results from a partial deficiency in PROTO oxidase, manifests itself with skin lesions similar to those of porphyria cutanea tarda combined with acute neurologic attacks. Hereditary coproporphyria, which is characterized by a deficiency in coproporphyrinogen oxidase, coded for by the CPOX gene, may also present with both acute neurologic attacks and cutaneous lesions. All other porphyrias are either skin- or nerve-predominant.[30]

Diagnosis

[edit]

Porphyrin studies

[edit]

Porphyria is diagnosed through biochemical analysis of blood, urine, and stool.[17][31] In general, urine estimation of porphobilinogen (PBG) is the first step if acute porphyria is suspected. As a result of feedback, the decreased production of heme leads to increased production of precursors, PBG being one of the first substances in the porphyrin synthesis pathway.[32] In nearly all cases of acute porphyria syndromes, urinary PBG is markedly elevated except for the very rare ALA dehydratase deficiency or in patients with symptoms due to hereditary tyrosinemia type I.[33] In cases of mercury- or arsenic poisoning-induced porphyria, other changes in porphyrin profiles appear, most notably elevations of uroporphyrins I & III, coproporphyrins I & III, and pre-coproporphyrin.[34]

As most porphyrias are rare conditions, general hospital labs typically do not have the expertise, technology, or staff time to perform porphyria testing. In general, testing involves sending samples of blood, stool, and urine to a reference laboratory.[17] All samples to detect porphyrins must be handled properly. Samples should be taken during an acute attack; otherwise a false negative result may occur. Samples must be protected from light and either refrigerated or preserved.[17]

If all the porphyrin studies are negative, one must consider pseudoporphyria. A careful medication review often will find the cause of pseudoporphyria.[citation needed]

Additional tests

[edit]

Further diagnostic tests of affected organs may be required, such as nerve conduction studies for neuropathy or an ultrasound of the liver. Basic biochemical tests may assist in identifying liver disease, hepatocellular carcinoma, and other organ problems.[35]

Management

[edit]

Acute porphyria

[edit]

Carbohydrate administration

[edit]

Often, empirical treatment is required if the diagnostic suspicion of a porphyria is high since acute attacks can be fatal. A high-carbohydrate diet is typically recommended; in severe attacks, a dextrose 10% infusion is commenced, which may aid in recovery by suppressing heme synthesis, which in turn reduces the rate of porphyrin accumulation. However, this can worsen cases of low blood sodium levels (hyponatraemia) and should be done with extreme caution as it can prove fatal.[36]

Heme analogs

[edit]

Hematin (trade name Panhematin) and heme arginate (trade name NormoSang) are the drugs of choice in acute porphyria in the United States and the United Kingdom respectively. These drugs need to be given very early in an attack to be effective; effectiveness varies amongst individuals. They are not curative drugs but can shorten attacks and reduce the intensity of an attack. Side effects are rare but can be serious. These heme-like substances theoretically inhibit ALA synthase and hence the accumulation of toxic precursors. In the United Kingdom, supplies of NormoSang are kept at two national centers; emergency supply is available from St Thomas's Hospital, London.[37] In the United States, Lundbeck manufactures and supplies Panhematin for infusion.[38]

Heme arginate (NormoSang) is used during crises but also in preventive treatment to avoid crises, one treatment every 10 days.[citation needed]

Any sign of low blood sodium (hyponatremia) or weakness should be treated with the addition of hematin, heme arginate, or even tin mesoporphyrin, as these are signs of impending syndrome of inappropriate antidiuretic hormone (SIADH) or peripheral nervous system involvement that may be localized or severe, progressing to bulbar paresis and respiratory paralysis.[citation needed]

Cimetidine

[edit]

Cimetidine has also been reported to be effective for acute porphyric crisis and possibly effective for long-term prophylaxis.[39]

Symptom control

[edit]

Pain is severe, frequently out of proportion to physical signs, and often requires the use of opiates to reduce it to tolerable levels. Pain should be treated as early as medically possible. Nausea can be severe; it may respond to phenothiazine drugs but is sometimes intractable. Hot baths and showers may lessen nausea temporarily, though caution should be used to avoid scalds or falls.[citation needed]

Early identification

[edit]

It is recommended that patients with a history of acute porphyria, and even genetic carriers, wear an alert bracelet or other identification at all times. This is in case they develop severe symptoms, or in case of accidents where there is a potential for drug exposure, and as a result they are unable to explain their condition to healthcare professionals. Some drugs are absolutely contraindicated for patients with any form of porphyria.[40]

Neurologic and psychiatric disorders

[edit]

Patients who experience frequent attacks can develop chronic neuropathic pain in extremities as well as chronic pain in the abdomen.[41] Intestinal pseudo-obstruction, ileus, intussusception, hypoganglionosis, and encopresis in children have been associated with porphyrias. This is thought to be due to axonal nerve deterioration in affected areas of the nervous system and vagal nerve dysfunction. Pain treatment with long-acting opioids, such as morphine, is often indicated, and, in cases where seizure or neuropathy is present, gabapentin is known to improve outcome.[42]

Seizures often accompany this disease. Most seizure medications exacerbate this condition. Treatment can be problematic: barbiturates especially must be avoided. Some benzodiazepines are safe and, when used in conjunction with newer anti-seizure medications such as gabapentin, offer a possible regimen for seizure control. Gabapentin has the additional feature of aiding in the treatment of some kinds of neuropathic pain.[42] Magnesium sulfate and bromides have also been used in porphyria seizures; however, development of status epilepticus in porphyria may not respond to magnesium alone. The addition of hematin or heme arginate has been used during status epilepticus.[43]

Depression often accompanies the disease and is best dealt with by treating the offending symptoms and if needed the judicious use of antidepressants. Some psychotropic drugs are porphyrinogenic, limiting the therapeutic scope. Other psychiatric symptoms such as anxiety, restlessness, insomnia, depression, mania, hallucinations, delusions, confusion, catatonia, and psychosis may occur.[44]

Underlying liver disease

[edit]

Some liver diseases may cause porphyria even in the absence of genetic predisposition. These include hemochromatosis and hepatitis C. Treatment of iron overload may be required.[2]

Patients with the acute porphyrias (AIP, HCP, VP) are at increased risk over their life for hepatocellular carcinoma (primary liver cancer) and may require monitoring. Other typical risk factors for liver cancer need not be present.[2]

Hormone treatment

[edit]

Hormonal fluctuations that contribute to cyclical attacks in women have been treated with oral contraceptives and luteinizing hormones to shut down menstrual cycles. However, oral contraceptives have also triggered photosensitivity and withdrawal of oral contraceptives has triggered attacks. Androgens and fertility hormones have also triggered attacks.[45] In 2019, givosiran was approved in the United States for the treatment of acute hepatic porphyria.[46][47]

Erythropoietic porphyria

[edit]

These are associated with accumulation of porphyrins in erythrocytes and are rare.

The pain, burning, swelling, and itching that occur in erythropoietic porphyrias (EP) generally require avoidance of bright sunlight. Most kinds of sunscreen are not effective, but SPF-rated long-sleeve shirts, hats, bandanas, and gloves can help. Chloroquine may be used to increase porphyrin secretion in some EPs.[17] Blood transfusion is occasionally used to suppress innate heme production.[citation needed]

The rarest is congenital erythropoietic porphyria (CEP), otherwise known as Gunther's disease. The signs may present from birth and include severe photosensitivity, brown teeth that fluoresce in ultraviolet light due to deposition of Type 1 porphyrins, and later hypertrichosis. Hemolytic anemia usually develops. Pharmaceutical-grade beta carotene may be used in its treatment.[48] A bone marrow transplant has also been successful in curing CEP in a few cases, although long-term results are not yet available.[49]

In December 2014, afamelanotide received authorization from the European Commission as a treatment for the prevention of phototoxicity in adult patients with EPP.[50] In a 2023 industry-funded phase 2 trial, dersimelagon, an orally administered, selective melanocortin 1 receptor agonist that increases levels of skin eumelanin, was reported to have increased the duration of symptom-free sunlight exposure and quality of life compared to placebo in patients with erythropoietic protoporphyria.[51]

Epidemiology

[edit]

Rates of all types of porphyria taken together have been estimated to be approximately one in 25,000 in the United States.[52] The worldwide prevalence has been estimated to be between one in 500 and one in 50,000 people.[53]

Porphyrias have been detected in all races and in many ethnic groups on every continent. There are high incidence reports of AIP in areas of India and Scandinavia. More than 200 genetic variants of AIP are known, some of which are specific to families, although some strains have proven to be repeated mutations.[citation needed]

History

[edit]

The underlying mechanism was first described by the German physiologist Felix Hoppe-Seyler in 1871,[54] and acute porphyrias were described by the Dutch physician Barend Stokvis in 1889.[55][56]

The links between porphyrias and mental illness have been noted for decades. In the early 1950s, patients with porphyrias (occasionally referred to as "porphyric hemophilia"[57]) and severe symptoms of depression or catatonia were treated with electroshock therapy.

Vampires and werewolves

[edit]

Porphyria has been suggested as an explanation for the origin of vampire and werewolf legends, based upon certain perceived similarities between the condition and the folklore.

In January 1964, L. Illis's 1963 paper 'On Porphyria and the Aetiology of Werewolves' was published in Proceedings of the Royal Society of Medicine. Later, Nancy Garden argued for a connection between porphyria and the vampire belief in her 1973 book Vampires. In 1985, biochemist David Dolphin's paper for the American Association for the Advancement of Science, 'Porphyria, Vampires, and Werewolves: The Aetiology of European Metamorphosis Legends', gained widespread media coverage, popularizing the idea.[citation needed]

The theory has been rejected by a few folklorists and researchers as not accurately describing the characteristics of the original werewolf and vampire legends nor the disease and as potentially stigmatizing people with porphyria.[58][59]

A 1995 article from the Postgraduate Medical Journal (via NIH) explains:

As it was believed that the folkloric vampire could move about freely in daylight hours, as opposed to the 20th century variant, congenital erythropoietic porphyria cannot readily explain the folkloric vampire but may be an explanation of the vampire as we know it in the 20th century. In addition, the folkloric vampire, when unearthed, was always described as looking quite healthy ("as they were in life"), whereas owing to disfiguring aspects of the disease sufferers would not have passed the exhumation test. Individuals with congenital erythropoietic porphyria do not crave blood. The enzyme (hematin) necessary to alleviate symptoms is not absorbed intact on oral ingestion, and drinking blood would have no beneficial effect on the sufferer. Finally, and most important, the fact that vampire reports were rampant in the 18th century, and that congenital erythropoietic porphyria is an extremely rare manifestation of a rare disease, makes it an unlikely explanation of the folkloric vampire.[60]

Notable cases

[edit]
  • George III of the United Kingdom. The mental illness exhibited by George III in the regency crisis of 1788 has inspired several attempts at retrospective diagnosis. The first, written in 1855, thirty-five years after his death, concluded that he had acute mania. M. Guttmacher, in 1941, suggested manic-depressive psychosis as a more likely diagnosis. The first suggestion that a physical illness was the cause of King George's mental derangement came in 1966, in a paper called "The Insanity of King George III: A Classic Case of Porphyria",[61] with a follow-up in 1968, "Porphyria in the Royal Houses of Stuart, Hanover and Prussia".[62] The papers, by a mother/son psychiatrist team, were written as though the case for porphyria had been proven, but the response demonstrated that many experts, including those more intimately familiar with the manifestations of porphyria, were unconvinced. Many psychiatrists disagreed with the diagnosis, suggesting bipolar disorder as far more probable. The theory is treated in Purple Secret,[63] which documents the ultimately unsuccessful search for genetic evidence of porphyria in the remains of royals suspected to have had it.[64] In 2005, it was suggested that arsenic (which is known to be porphyrogenic) given to George III with antimony may have caused his porphyria.[65] This study found high levels of arsenic in King George's hair. In 2010, one analysis of historical records argued that the porphyria claim was based on spurious and selective interpretation of contemporary medical and historical sources.[66] The mental illness of George III is the basis of the plot in The Madness of King George, a 1994 British film based upon the 1991 Alan Bennett play, The Madness of George III. The closing credits of the film include the comment that the King's symptoms suggest that he had porphyria, and note that the disease is "periodic, unpredictable, and hereditary". The traditional argument that George III did not have porphyria, but rather bipolar disorder, is thoroughly defended by Andrew Roberts in his new biography The Last King of America.[67]
  • Descendants of George III. Among other descendants of George III theorized by the authors of Purple Secret to have had porphyria (based on analysis of their extensive and detailed medical correspondence) were his great-great-granddaughter Princess Charlotte of Prussia (Emperor William II's eldest sister) and her daughter Princess Feodora of Saxe-Meiningen. They uncovered better evidence that George III's great-great-great-grandson Prince William of Gloucester was reliably diagnosed with variegate porphyria.[68]
  • Mary, Queen of Scots. It is believed that Mary, Queen of Scots, King George III's ancestor, also had acute intermittent porphyria,[69] although this is subject to much debate. It is assumed she inherited the disorder, if indeed she had it, from her father, James V of Scotland. Both father and daughter endured well-documented attacks that could fall within the constellation of symptoms of porphyria.[citation needed]
  • Maria I of Portugal. Maria I—known as Maria the Pious or Maria the Mad because of both her religious fervor and her acute mental illness, which made her incapable of handling state affairs after 1792—is also thought to have had porphyria. Francis Willis, the physician who treated George III, was even summoned by the Portuguese court but returned to England after the court limited the treatments he could oversee. Contemporary sources, such as Secretary of State for Foreign Affairs Luís Pinto de Sousa Coutinho, noted that the queen had ever-worsening stomach pains and abdominal spasms: hallmarks of porphyria.[70]
  • Vincent van Gogh. Other commentators have suggested that Vincent van Gogh may have had acute intermittent porphyria.[71]
  • King Nebuchadnezzar of Babylon. The description of this king in Daniel 4 suggests to some that he had porphyria.[citation needed]
  • Physician Archie Cochrane. He was born with porphyria, which caused health problems throughout his life.[72]
  • Paula Frías Allende. The daughter of the Chilean novelist Isabel Allende. She fell into a porphyria-induced coma in 1991,[73] which inspired Isabel to write the memoir Paula, dedicated to her.
  • Tommy Steele. London-born entertainer, frequently hospitalized as a child due to the condition.

Uses in literature

[edit]

Stated or implied references to porphyria are included in some literature, particularly gothic literature. These include the following:

  • The condition is the name of the title character in the gothic poem "Porphyria's Lover", by Robert Browning.[citation needed]
  • The condition is heavily implied to be the cause of the symptoms suffered by the narrator in the gothic short story "Lusus Naturae", by Margaret Atwood. Some of the narrator's symptoms resemble those of porphyria, and one passage of the story states that the name of the narrator's disease "had some Ps and Rs in it." [citation needed]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Porphyria

View on Grokipedia
from Grokipedia
Porphyria is a group of rare metabolic disorders caused by partial deficiencies in the enzymes involved in , leading to the accumulation of toxic porphyrins and their precursors in the body. These disorders primarily manifest with neurovisceral symptoms, cutaneous lesions, or a combination thereof, and are predominantly inherited through genetic mutations, although certain forms can be acquired. The porphyrias are broadly classified into two main categories based on predominant organ involvement: acute hepatic porphyrias, which affect the and cause episodic attacks, and cutaneous porphyrias, which primarily impact the skin through . There are eight recognized types, including four acute forms—acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), and delta-aminolevulinic acid dehydratase deficiency porphyria (ADP)—and four cutaneous forms, such as porphyria cutanea tarda (PCT), congenital erythropoietic porphyria (CEP), (EPP), and hepatoerythropoietic porphyria (HEP). AIP is the most common acute type, while PCT is the most prevalent overall, often presenting later in life. Most porphyrias result from autosomal dominant mutations in genes encoding the eight enzymes of the pathway, with incomplete meaning not all gene carriers develop symptoms. PCT, however, is frequently sporadic and triggered by environmental factors such as excessive alcohol consumption, hepatitis C infection, , or use, rather than solely genetic inheritance. Symptoms in acute porphyrias typically emerge after and are more common in women, often precipitated by drugs, , hormonal changes, or stress, leading to severe , neurological deficits like or seizures, autonomic instability, and psychiatric disturbances. Cutaneous manifestations include painful , skin fragility, blistering, and scarring upon sun exposure, with chronic complications such as , , or possible in untreated cases. Epidemiologically, porphyrias affect fewer than 200,000 individuals , with global prevalence varying by type; for instance, the prevalence of AIP is estimated at 5–10 per 100,000 individuals (genetic carriers), though symptomatic cases are rarer, occurring in about 1 per 100,000 or less and the U.S., while rarer forms like CEP have an incidence of less than 1 per million. relies on clinical suspicion, biochemical testing for porphyrin levels in , , or stool, and genetic confirmation, with management focusing on avoiding triggers, symptomatic relief with or givosiran, and, in severe cases, for hepatic involvement.

Overview

Definition and classification

Porphyria refers to a group of mostly inherited metabolic disorders arising from partial deficiencies in the enzymes of the heme biosynthetic pathway, which results in the overproduction and accumulation of porphyrins or their precursors. , a critical component of , is essential for oxygen transport in the blood, and disruptions in its synthesis underlie these conditions. Porphyrias are broadly classified into two categories based on the primary site of the enzymatic defect and porphyrin accumulation: hepatic porphyrias, where the abnormalities originate mainly in the liver, and erythropoietic porphyrias, where they occur predominantly in the bone marrow. This organ-based classification helps distinguish the metabolic origins, with hepatic forms often involving liver-specific enzyme issues and erythropoietic forms linked to red blood cell production. Within these categories, porphyrias are further subdivided according to their predominant clinical presentations: those associated with acute neurovisceral attacks, which include , , hereditary coproporphyria, and ALA dehydratase deficiency porphyria, and those primarily featuring cutaneous manifestations, such as , congenital erythropoietic porphyria, , and hepatoerythropoietic porphyria. The acute forms are generally hepatic, while cutaneous forms can be either hepatic or erythropoietic, reflecting the varied tissue impacts of buildup. The eight major types of porphyria are as follows:
  • Acute intermittent porphyria (AIP): A hepatic porphyria inherited in an autosomal dominant manner.
  • ALA dehydratase deficiency porphyria (ADP): A rare hepatic porphyria inherited in an autosomal recessive manner.
  • Congenital erythropoietic porphyria (CEP): An erythropoietic porphyria inherited in an autosomal recessive manner.
  • Erythropoietic protoporphyria (EPP): An erythropoietic porphyria inherited in an autosomal recessive manner.
  • Hereditary coproporphyria (HCP): A hepatic porphyria inherited in an autosomal dominant manner.
  • Hepatoerythropoietic porphyria (HEP): A rare form affecting both liver and bone marrow, inherited in an autosomal recessive manner.
  • Porphyria cutanea tarda (PCT): A hepatic porphyria that occurs in two forms—Type I, which is sporadic and non-hereditary, and Type II, which is hereditary and inherited in an autosomal dominant manner.
  • Variegate porphyria (VP): A hepatic porphyria inherited in an autosomal dominant manner.
This classification highlights that most acute porphyrias follow autosomal dominant inheritance, while several erythropoietic forms are autosomal recessive, with PCT uniquely presenting both sporadic and hereditary variants.

Heme biosynthesis pathway

is a conserved essential for producing , a in proteins such as , , and , which is vital for oxygen transport, , and processes in aerobic organisms. The pathway consists of eight enzymatic steps that convert and into , with intermediates accumulating if any step is impaired. This process occurs primarily in mammalian liver and erythroid cells, spanning both mitochondria and , and is tightly regulated to match cellular demand. The pathway begins in the mitochondria, where the rate-limiting 5-aminolevulinic acid synthase (ALAS) catalyzes the condensation of and to form δ-aminolevulinic acid (ALA), requiring as a cofactor. ALA is then transported to the for the next steps. There, ALA dehydratase (also known as porphobilinogen synthase) dimerizes two ALA molecules into porphobilinogen (PBG), a derivative that serves as the building block for the ring. Four PBG units are subsequently polymerized by porphobilinogen deaminase (hydroxymethylbilane synthase) to form the linear hydroxymethylbilane. This intermediate is cyclized and rearranged by uroporphyrinogen III synthase to yield uroporphyrinogen III, the asymmetric precursor to all biologically active porphyrins; uroporphyrinogen I, the symmetric isomer, is typically degraded. Decarboxylation of uroporphyrinogen III by uroporphyrinogen in the produces coproporphyrinogen III, featuring methyl and propionate side chains on the ring. Coproporphyrinogen III is shuttled back to the mitochondria, where coproporphyrinogen converts it to protoporphyrinogen IX through oxidative decarboxylation of two propionate groups to vinyl substituents. Protoporphyrinogen then dehydrogenates protoporphyrinogen IX to , the final intermediate with four methyl and four vinyl groups. The pathway concludes in the mitochondria with ferrochelatase inserting ferrous iron (Fe²⁺) into to form , the predominant isoform. The subcellular localization alternates: the first step and final three steps occur in the mitochondria, while steps two through five take place in the , necessitating transport of intermediates across membranes. Key intermediates include ALA (a five-carbon ), PBG (a monopyrrole), uroporphyrinogen III (a reduced octacarboxyl porphyrinogen), coproporphyrinogen III (a reduced tetracarboxyl porphyrinogen), and (a fully oxidized metal-free ). Regulation primarily occurs at the ALAS step, with two isoforms: ALAS1 (, expressed ubiquitously but inducible in liver) and ALAS2 (erythroid-specific). exerts feedback inhibition on ALAS1 by repressing transcription, destabilizing mRNA, inhibiting mitochondrial import, and promoting proteasomal degradation, ensuring heme levels do not exceed cellular needs. ALAS2 is instead regulated by iron-responsive elements that enhance in response to iron availability during . The heme biosynthesis pathway is evolutionarily ancient and highly conserved, with the core segment from ALA to uroporphyrinogen III—catalyzed by , , and —shared across prokaryotes and eukaryotes, reflecting its origin in early aerobic life. Variations exist post-uroporphyrinogen III, such as oxygen-dependent versus independent enzymes in anaerobes, but the eukaryotic pathway predominates in vertebrates, with ALAS isoforms arising from approximately 550 million years ago. Defects in any of the eight enzymes can lead to the accumulation of pathway intermediates, characteristic of porphyrias.

Signs and symptoms

Acute porphyrias

Acute porphyrias, also known as acute hepatic porphyrias, are characterized by recurrent episodes of severe neurovisceral and autonomic symptoms during acute attacks. The hallmark symptom is intense , often described as diffuse or localized and poorly responsive to analgesics, accompanied by gastrointestinal disturbances such as , , and . Autonomic involvement manifests as , , excessive sweating, , and fluctuations in , contributing to the overall distress of the attack. Neurological symptoms include and , which may present as tingling, numbness, or , particularly affecting the limbs and potentially progressing to involve respiratory muscles. Psychiatric disturbances are common, ranging from anxiety and confusion to hallucinations, agitation, and seizures, affecting up to 80% of attacks in some cases. These manifestations arise from dysfunction in the central, peripheral, and autonomic nervous systems, distinguishing acute porphyrias from cutaneous forms that involve without prominent neurovisceral features. Attacks typically develop over hours to days and last from days to weeks, with symptoms often resolving upon cessation of precipitating factors, though full recovery can take longer in severe instances. In progressive or untreated cases, complications may include , , or , which can be life-threatening. Acute intermittent porphyria (AIP), the most common form of acute porphyria, exemplifies these symptoms with recurrent attacks predominantly in women after , often linked to the . In AIP, and autonomic instability frequently precede neurological and psychiatric features, with episodes recurring intermittently over years.

Cutaneous porphyrias

Cutaneous porphyrias are a subset of porphyrias characterized by the accumulation of porphyrins in the , leading to triggered by () exposure. This arises when photoactivated porphyrins generate , causing oxidative damage to tissues, particularly in sun-exposed areas such as the hands, face, and forearms. Common reactions include skin fragility, where minor trauma leads to erosions, and the formation of vesicles or bullae that may rupture and heal with crusting. In (PCT), the most prevalent cutaneous form, symptoms manifest as chronic blistering and milia formation on sun-exposed skin, often accompanied by (excessive hair growth), , and with scarring. These lesions typically appear in mid-adulthood and result from mechanical fragility rather than immediate pain, with healing leaving atrophic scars and potential nail dystrophy. In contrast, (EPP) presents with acute, non-blistering , featuring intense burning pain, pruritus, and within minutes of light exposure, without significant scarring but potentially leading to waxy thickening of the skin over time. Congenital erythropoietic porphyria (CEP), a rarer and more severe variant, involves severe blistering and erosions from infancy, progressing to mutilating scarring, , and erythrodontia (red-brown teeth discoloration), alongside and reddish urine due to excretion. Unlike acute porphyrias, cutaneous forms exhibit a predominantly chronic course, with progressive damage accumulating over years from repeated light-induced insults, rather than episodic crises. This leads to long-term cosmetic and functional impairments, such as finger contractures in severe cases like CEP, without the visceral or neurological involvement seen in other porphyrias. Systemic effects are generally confined to the , though some types like PCT may involve mild hepatic abnormalities due to deposition. Certain porphyrias, such as , can overlap with dual cutaneous and acute presentations, but symptoms align closely with those described here.

Causes

Genetic factors

Porphyrias are primarily inherited disorders resulting from partial deficiencies in the enzymes of the heme biosynthetic pathway, leading to the accumulation of toxic porphyrin precursors. These deficiencies arise from germline mutations in specific genes encoding these enzymes, with most forms being monogenic. The majority of acute hepatic porphyrias, such as acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), and variegate porphyria (VP), follow an autosomal dominant inheritance pattern, where a single mutated allele from one parent confers a 50% risk of transmission to offspring. In contrast, erythropoietic forms like congenital erythropoietic porphyria (CEP) and erythropoietic protoporphyria (EPP) are autosomal recessive, requiring biallelic mutations from both parents for disease manifestation, with heterozygous carriers remaining asymptomatic. A rare exception is 5-aminolevulinic acid dehydratase (ALAD) deficiency porphyria (ADP), also autosomal recessive. Specific mutations have been identified in key genes; for instance, in AIP, over 400 pathogenic variants in the HMBS gene, which encodes hydroxymethylbilane synthase (also known as porphobilinogen deaminase), reduce enzyme activity to approximately 50% of normal levels in heterozygotes. Similarly, mutations in the UROD gene encoding uroporphyrinogen decarboxylase underlie familial (type 2) (PCT), a cutaneous form, while CPOX and PPOX mutations affect coproporphyrinogen oxidase and protoporphyrinogen oxidase in HCP and VP, respectively. These partial enzyme deficiencies typically do not cause symptoms in isolation but can lead to precursor accumulation under certain conditions. Penetrance in autosomal dominant porphyrias is notably low, often ranging from 1% to 10%, which accounts for the presence of many carriers who harbor the but never develop clinical manifestations. Modifying factors, including hormonal influences such as elevated levels, contribute to this variable expressivity, with women showing a higher risk of symptomatic attacks due to menstrual cycles, , or exogenous hormones. is essential for affected families, providing information on risks, penetrance variability, and strategies to identify carriers through family testing, thereby enabling informed reproductive decisions and avoidance of exacerbating factors. Although most porphyrias are hereditary, non-hereditary forms are not uncommon; for example, the majority of (PCT) cases (type 1, approximately 80%) are sporadic and arise from environmental or acquired factors rather than mutations. Rare toxic forms also exist; for example, can inhibit ALAD activity, mimicking the biochemical and clinical features of ADP by causing elevated urinary δ-aminolevulinic acid levels.

Environmental triggers

Environmental triggers play a critical role in precipitating acute attacks of porphyria in genetically susceptible individuals by disrupting the balance in the biosynthetic pathway. These factors increase the demand for synthesis, leading to overproduction of toxic porphyrin precursors that accumulate due to underlying enzymatic deficiencies. Common precipitants include certain medications, such as barbiturates and sulfonamides, which are known to induce hepatic δ-aminolevulinic acid synthase (ALAS1), the rate-limiting enzyme in production. Alcohol consumption, or caloric restriction, , physical or emotional stress, infections, and hormonal changes associated with the in women are also frequent triggers. For instance, excessive alcohol intake can exacerbate attacks by both inducing ALAS1 and causing direct hepatic . The primary mechanism involves the induction of hepatic ALAS1, which upregulates the biosynthetic pathway despite partial enzymatic blocks, resulting in accumulation of neurotoxic precursors like δ-aminolevulinic acid (ALA) and porphobilinogen (PBG). This induction can occur through heme depletion or direct activation by exogenous chemicals, amplifying substrate buildup proximal to the deficient enzyme. For cutaneous porphyrias, environmental factors can trigger or exacerbate symptoms differently. In (PCT), the most common form, onset is often precipitated by factors such as excessive alcohol consumption, hepatitis C or infection, (e.g., from hemochromatosis or multiple transfusions), , and exposure to estrogens (e.g., oral contraceptives). These inhibit uroporphyrinogen decarboxylase activity or promote hepatic accumulation, leading to and skin lesions. In other cutaneous forms like (EPP), while primarily genetic, environmental factors such as or certain medications may influence severity, though ultraviolet light exposure directly triggers symptoms. To mitigate risks, individuals with acute porphyrias should avoid porphyrinogenic drugs; resources like the American Porphyria Foundation's drug database classify medications as safe, possibly unsafe, or unsafe based on their potential to trigger attacks. For example, barbiturates are categorized as unsafe due to strong ALAS1 induction, while many common analgesics like acetaminophen are generally safe. Adopting lifestyle modifications, such as maintaining adequate intake to suppress ALAS1 and avoiding alcohol and smoking, further reduces attack frequency. For cutaneous forms like PCT, management of triggers involves treating underlying conditions (e.g., hepatitis C) and reducing exposure to precipitants like alcohol and iron. Many acute attacks—often identifiable in a substantial proportion of cases—are linked to these modifiable factors, underscoring the importance of trigger avoidance for disease management.

Pathophysiology

Porphyrin accumulation mechanisms

Porphyrias result from partial deficiencies in one of the eight enzymes involved in , causing the buildup of pathway intermediates upstream of the defective step. These blocks disrupt the normal flow, leading to overproduction and accumulation of precursors or , depending on the location of the enzymatic impairment. In upstream deficiencies, such as those affecting early enzymes, water-soluble precursors like δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) predominate and are often excreted in or plasma. For instance, in due to hydroxymethylbilane (HMBS) deficiency, ALA and PBG accumulate significantly during attacks because the block prevents their conversion to hydroxymethylbilane. In contrast, downstream blocks involve later enzymes and result in the accumulation of hydrophobic porphyrins, which are less readily excreted and tend to deposit in tissues. Examples include uroporphyrinogen decarboxylase deficiency in , leading to hepatic buildup of uroporphyrins, or ferrochelatase deficiency in , causing accumulation in erythrocytes. This distinction influences the clinical manifestations, with upstream accumulations more associated with acute neurovisceral effects and downstream with chronic cutaneous damage. The accumulation is amplified by impaired feedback regulation in the heme pathway. Heme normally exerts on hepatic ALA synthase 1 (ALAS1), the rate-limiting enzyme, by repressing its transcription, mitochondrial import, and activity; reduced heme levels from enzymatic blocks weaken this inhibition, derepressing ALAS1 and driving excessive production of ALA and subsequent intermediates. This dysregulation is particularly pronounced in hepatic porphyrias, where inducible factors like drugs or hormones can further upregulate ALAS1 via the pregnane X receptor, exacerbating precursor overproduction. Organ-specific accumulation patterns reflect the site of heme synthesis and enzyme expression. In acute hepatic porphyrias, the liver overproduces ALA and PBG due to high ALAS1 activity, with precursors entering the bloodstream but showing limited penetration, though they affect peripheral nerves and the autonomic system. In erythropoietic porphyrias, such as congenital erythropoietic porphyria or , deficiencies in bone marrow-expressed enzymes like uroporphyrinogen III synthase or ferrochelatase lead to buildup in developing erythrocytes, followed by deposition in the skin and other tissues upon circulation. The accumulated intermediates exert toxicity through distinct biochemical mechanisms. Porphyrin precursors like ALA are neurotoxic, functioning as partial agonists at GABA_A receptors to displace GABA, reduce receptor density via oxidative damage, and disrupt neurotransmitter balance; ALA also promotes oxidative stress by auto-oxidizing to generate superoxide and hydroxyl radicals, leading to lipid peroxidation, mitochondrial dysfunction, and iron dysregulation in neurons and Schwann cells. PBG contributes modestly to this neurotoxicity, potentially through similar oxidative pathways. Meanwhile, porphyrins in cutaneous forms induce photosensitization: upon absorbing visible light (primarily 400–410 nm in the Soret band), they transition to an excited triplet state and transfer energy to ground-state molecular oxygen via Type II photochemistry, producing singlet oxygen and other reactive oxygen species (ROS) that oxidize lipids, proteins, and DNA in skin cells, causing inflammation, blistering, and fibrosis. Porphyrins further drive protein aggregation and cellular damage through ROS-mediated oxidative stress, independent of light exposure in some contexts.

Tissue-specific effects

In acute porphyrias, accumulation of δ-aminolevulinic acid (ALA) and porphobilinogen (PBG) primarily affects the by inducing , leading to axonal neuropathy. ALA, in particular, impairs neuronal function through inhibition of Na⁺/K⁺-ATPase activity, disrupting sodium channel-mediated and contributing to motor-predominant axonal damage. Additionally, ALA promotes mitochondrial dysfunction by causing , loss of transmembrane potential, and reduced , which exacerbates energy deficits and neuronal degeneration in peripheral nerves. PBG contributes secondarily by further disrupting synthesis and balance, though its direct toxicity is less pronounced than ALA's. Cutaneous porphyrias manifest skin-specific effects due to porphyrin accumulation in dermal tissues, where photoactivation generates (ROS) that damage endothelial and epidermal cells. In , catalyzes ROS production upon visible light exposure, leading to immediate , , and through vascular leakage and complement activation. Chronic exposure results in dermal , manifesting as waxy thickening and scarring on sun-exposed areas like the knuckles and nose, driven by repeated ROS-induced tissue remodeling. In , uroporphyrin accumulation similarly triggers ROS-mediated fragility and blistering, with subepidermal progressing to milia formation and scleroderma-like induration in severe cases. Porphyria cutanea tarda involves hepatic porphyrin overload, where impaired uroporphyrinogen decarboxylase activity causes accumulation of highly carboxylated s in hepatocytes, leading to secondary . This overload promotes and iron-mediated damage, resulting in chronic and . The condition significantly increases the risk of , with a 20-fold elevation compared to the general population and a 3-fold increase relative to chronic alcohol abusers, attributed to persistent porphyrin toxicity and associated factors like . Beyond primary sites, acute porphyrias impose cardiovascular strain through , impairing parasympathetic and sympathetic regulation of and . This manifests as , , and reflex test abnormalities during attacks, with partial persistence in remission due to small-fiber dysfunction. In erythropoietic porphyrias like congenital erythropoietic porphyria, porphyrin-laden erythrocytes undergo photo-induced , causing chronic and compensatory from reticuloendothelial hyperactivity.

Diagnosis

Clinical assessment

The clinical assessment of suspected porphyria begins with a detailed history taking to identify patterns suggestive of the disorder. Patients often report episodic, severe that is poorly localized and non-colicky, frequently accompanied by neurological symptoms such as , , or confusion, which may recur in relation to triggers like certain medications, , hormonal changes, or alcohol exposure. A family history of similar unexplained symptoms, including recurrent abdominal crises or , is crucial to elicit, given the autosomal dominant in many forms. For cutaneous variants, patients describe patterns of manifesting as burning or itching on sun-exposed , often worsening seasonally or with specific exposures. Physical examination focuses on corroborating historical features without signs of surgical emergencies. Abdominal palpation typically reveals diffuse tenderness without rebound or guarding indicative of , while vital signs may show and during acute episodes. Neurological evaluation can uncover motor deficits such as or sensory changes, particularly in the extremities, reflecting axonal neuropathy. In cases involving cutaneous involvement, inspection of sun-exposed areas may reveal characteristic skin lesions, including fragile blisters, erosions, , or scarring on the hands, face, or arms. Differential diagnosis requires ruling out mimics that present with overlapping features, such as Guillain-Barré syndrome for acute neuropathy, for abdominal pain and neuropathy, or for gastrointestinal symptoms and potential psychiatric manifestations. Other considerations include from surgical causes, psychiatric disorders, or electrolyte imbalances unrelated to porphyria. Recognition of life-threatening features is essential for urgent management; severe , often due to of inappropriate antidiuretic hormone secretion, or seizures complicating acute attacks demand immediate intervention to prevent complications like . If clinical suspicion persists, targeted biochemical testing is warranted to confirm the .

Biochemical testing

Biochemical testing for porphyria involves measuring porphyrin precursors and porphyrins in biological fluids to identify characteristic accumulation patterns that distinguish acute from cutaneous forms. These tests are essential for confirming clinical suspicion, particularly during symptomatic episodes, as they detect disruptions in . Urine analysis serves as the primary initial test, focusing on delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), which are markedly elevated during acute attacks in acute hepatic porphyrias such as (AIP), hereditary coproporphyria (HCP), and (VP). PBG levels exceeding 10 times the upper reference limit (typically >20 μmol/L or >10 mg/g ) are a hallmark, with high specificity when measured via reliable methods like liquid chromatography-mass spectrometry (LC-MS). For cutaneous porphyrias like (PCT) or congenital erythropoietic porphyria (CEP), urine total porphyrins are assessed, showing elevations in uroporphyrins or coproporphyrins (normal <35 nmol/mmol ). Samples should be random or spot urine, normalized to , and protected from light to prevent degradation. Fecal and blood tests provide further differentiation, particularly for VP and HCP, where coproporphyrin III in feces is disproportionately elevated (normal total fecal porphyrins <200 nmol/g dry weight), often with a coproporphyrin III:I ratio >1.5 in HCP. Blood tests measure erythrocyte protoporphyrins, which are increased in (EPP) (normal 0.4–1.7 μmol/L total, with >80% metal-free protoporphyrin). Plasma is key for EPP, detecting a diagnostic emission peak at 626–634 nm due to accumulation (normal plasma total porphyrins <19 nmol/L). These tests are recommended after initial urine screening to refine the diagnosis. Testing timing is critical, as ALA and PBG levels normalize within days to weeks between acute attacks, potentially leading to false-negative results if performed during asymptomatic or latent phases; thus, prompt sample collection during symptoms is advised, with urine stable for 24 hours at room temperature or longer if refrigerated. Enzyme assays, such as porphobilinogen deaminase activity for AIP (normal 6–20 nmol/s/L, reduced by ~50% in heterozygotes), offer confirmatory support but have limitations due to overlapping normal ranges and are less commonly used in favor of metabolite profiling. Overall limitations include nonspecific elevations from conditions like liver disease or lead poisoning, and methodological variability (e.g., false negatives with outdated colorimetric assays for PBG), underscoring the need for specialized laboratories.

Genetic confirmation

Genetic confirmation of porphyria involves molecular testing to identify pathogenic variants in genes associated with heme biosynthesis, typically pursued after biochemical evidence suggests a diagnosis. This approach provides definitive identification of the specific type of porphyria and enables predictive testing for at-risk family members. Methods for genetic confirmation include targeted DNA sequencing of individual genes implicated in specific porphyrias, such as the HMBS gene for , which detects over 97% of known disease-causing mutations. For broader evaluation, next-generation sequencing (NGS) panels analyze multiple genes simultaneously, such as panels covering 11 genes including ALAD, ALAS2, CLPX, CPOX, FECH, GATA1, HFE, HMBS, PPOX, UROD, and UROS, using sequence capture followed by PCR and Sanger sequencing for validation. These techniques identify single nucleotide variants, copy number changes, and other alterations in genes encoding enzymes critical to the heme pathway, like HMBS for . Indications for genetic testing arise after biochemical confirmation of elevated porphyrin precursors, such as porphobilinogen in acute porphyrias, to pinpoint the underlying mutation. It is also recommended for family screening of asymptomatic relatives of affected individuals, atypical clinical presentations where biochemical results are inconclusive, and to guide personalized management in confirmed cases. Identified variants are classified as pathogenic if they clearly disrupt enzyme function, such as the HMBS c.517C>T (p.R173W) mutation in AIP, or as variants of uncertain significance (VUS) when their clinical impact requires further biochemical correlation. Many porphyrias exhibit incomplete , with carriers of pathogenic variants like those in HMBS for AIP showing clinical manifestations in only 1-10% of cases, necessitating careful interpretation and monitoring for environmental triggers in asymptomatic individuals. Genetic testing is available through specialized clinical laboratories, including those affiliated with the International Porphyria Network (Ipnet) and facilities like Genetic Testing Laboratory or Laboratories, often integrated with to discuss inheritance patterns and implications. Turnaround times typically range from 14 to 21 days, with some programs offering free testing for acute porphyrias through organizations like the American Porphyria Foundation, though costs vary by region and insurance coverage.

Treatment

Management of acute attacks

Management of acute attacks in porphyria primarily focuses on rapid intervention to suppress hepatic synthesis, alleviate symptoms, and prevent complications during neurovisceral crises. Hospitalization is indicated for severe attacks characterized by intense unresponsive to oral , neurological involvement such as seizures or motor weakness, persistent leading to , or electrolyte imbalances like . Patients with mild attacks may be managed outpatient initially, but escalation to is common if symptoms worsen. Intravenous glucose administration, known as , serves as an initial to inhibit delta-aminolevulinic acid (ALA) synthase and reduce porphyrin precursor production, particularly in mild to moderate attacks or while awaiting . A typical regimen involves infusing approximately 300 g of carbohydrates daily, such as 3 liters of 10% glucose solution, with close monitoring of blood glucose to avoid . This approach is most effective early in the attack and should be transitioned to for severe cases. Heme therapy is the cornerstone of treatment for moderate to severe acute attacks, providing exogenous to repress ALA synthase induction and halt porphyrin accumulation. Intravenous (as Panhematin) or heme arginate is administered at a dose of 3-4 mg/kg body weight daily for 3-4 days, ideally via a to minimize , with infusion over at least 30-60 minutes after reconstitution in . may extend up to 14 days in cases or those with neuropathy, with repeat courses possible if attacks recur during the same . Symptomatic relief is essential to support patient comfort and recovery. Pain, often the most debilitating symptom, is managed with opioids such as or via pumps, escalating to intensive care input if needed; non-opioid options like acetaminophen or may suffice for milder pain, while avoiding porphyrinogenic drugs like certain barbiturates. Antiemetics including or control nausea and vomiting, and beta-blockers like address autonomic instability such as or , administered cautiously to prevent . Constipation from opioids is treated with safe laxatives like . Close monitoring is critical to detect and manage complications during hospitalization. Vital signs, fluid balance, and neurological status should be assessed frequently, with particular attention to electrolytes—hyponatremia, a common risk from vomiting or syndrome of inappropriate antidiuretic hormone secretion, requires slow correction using 0.9% saline at rates not exceeding 6-12 mmol/L per day to avoid osmotic demyelination syndrome. Serial measurements of urinary ALA and porphobilinogen (PBG) levels guide response to therapy, and respiratory function is evaluated in cases of potential bulbar involvement. For patients with recurrent acute attacks, givosiran, an therapeutic targeting ALA synthase 1, may be initiated as a bridge to long-term prophylaxis while continuing standard acute treatments like during breakthroughs. Administered subcutaneously at 2.5 mg/kg monthly, it reduces attack frequency but does not replace immediate .

Long-term preventive strategies

Long-term preventive strategies for acute porphyria focus on minimizing exposure to triggers and implementing proactive interventions to reduce the frequency and severity of attacks, particularly in patients with recurrent episodes. These approaches emphasize , lifestyle adjustments, and targeted therapies to maintain and prevent precursor accumulation. By addressing modifiable risk factors and providing ongoing support, such strategies can significantly improve and decrease healthcare utilization. Lifestyle modifications form the cornerstone of prevention, centering on trigger avoidance to suppress hepatic ALA synthase activity. Patients are advised to consult validated resources, such as the European Porphyria Network (EPNET) database, for lists of safe and unsafe medications, avoiding porphyrinogenic drugs like barbiturates, sulfonamides, and certain anticonvulsants that induce enzymes. Dietary management includes consuming regular, balanced meals to prevent fasting or caloric restriction, which can precipitate attacks by altering and increasing porphyrin production; nutritional counseling is recommended to ensure adequate intake without extremes. Smoking cessation is critical, as use has been identified as a trigger in up to 6% of symptomatic cases, potentially exacerbating hepatic stress and attack risk. Limiting alcohol intake is also essential, given its role in inducing microsomal enzymes and disrupting synthesis. Prophylactic pharmacological interventions are considered for patients with frequent attacks, typically defined as four or more per year. Periodic administration of low-dose heme preparations, such as heme arginate (Normosang) or hemin (Panhematin), at intervals like weekly infusions, represses ALA synthase and has demonstrated reductions in attack frequency and severity, particularly in women with recurrent episodes. For premenopausal women where menstrual cycles trigger attacks in about 17% of cases, gonadotropin-releasing hormone (GnRH) analogs, such as leuprolide, can suppress ovulation and mitigate hormonal fluctuations, offering effective prophylaxis with careful monitoring for side effects like bone density loss. These therapies should be individualized based on attack history and biochemical markers. Ongoing monitoring and supportive measures ensure early detection of risks and empower patients through education. Annual biochemical screening, including urinary porphobilinogen (PBG) and (ALA) levels, helps assess disease activity and guide adjustments to preventive plans. is recommended for affected individuals and families to discuss inheritance patterns—typically autosomal dominant for acute hepatic porphyrias—and facilitate predictive testing for at-risk relatives, promoting informed . programs, often delivered through registries like the American Porphyria Foundation's ELEVATE registry, provide resources on trigger recognition, safe practices, and self-management, fostering adherence and community support. In rare cases of severe recessive erythropoietic porphyrias, such as congenital erythropoietic porphyria or uroporphyrinogen III synthase deficiency, (HSCT) offers a curative option by replacing defective erythroid precursors, though it carries significant risks and is reserved for life-threatening manifestations like severe or unresponsive to other therapies.

Therapies for cutaneous forms

Therapies for cutaneous porphyrias primarily aim to alleviate skin manifestations caused by porphyrin accumulation in the skin, which leads to photosensitivity, blistering, and scarring upon exposure to visible light. These treatments target specific subtypes, including porphyria cutanea tarda (PCT), erythropoietic protoporphyria (EPP), and congenital erythropoietic porphyria (CEP), by reducing porphyrin levels or enhancing photoprotection. In PCT, the most common cutaneous porphyria, treatment focuses on depleting hepatic iron stores and mobilizing uroporphyrins to induce remission. Repeated phlebotomy, typically removing 250-500 mL of blood every 1-2 weeks until ferritin levels normalize, effectively reduces iron overload and interrupts the inhibition of uroporphyrinogen decarboxylase, leading to biochemical and clinical improvement in most patients within 6-12 months. Alternatively, low-dose hydroxychloroquine (100 mg twice weekly) promotes hepatic porphyrin excretion and achieves comparable efficacy to phlebotomy, with remission rates of 70-90% and fewer side effects in patients intolerant to venesection. Lifestyle modifications, such as strict avoidance of alcohol, which exacerbates hepatic porphyrin production, are essential adjuncts to prevent relapse. For EPP, characterized by painful without blistering, therapies enhance skin tolerance to light. , a synthetic analog of α-melanocyte-stimulating administered as a subcutaneous implant every 60 days, stimulates eumelanin production to provide broad-spectrum photoprotection, significantly increasing pain-free light exposure time by 2-6 hours in clinical trials. Oral beta-carotene supplementation (90-180 mg/day for adults) acts as an and light filter, modestly improving in about 20-30% of patients, though evidence of benefit is limited and variable. In CEP, a severe congenital form with hemolytic anemia and mutilating skin lesions, supportive measures include hypertransfusion to suppress endogenous and reduce production, often maintaining levels above 10 g/dL. may further decrease and output in select cases, providing partial symptom relief. Allogeneic transplantation offers a curative option, with successful engraftment leading to normalization of levels and resolution of in over 80% of pediatric patients treated early. Regardless of subtype, rigorous sun protection is a cornerstone of management to prevent acute phototoxic reactions. Broad-spectrum sunscreens with high UVA/UVB protection (SPF 50+), combined with opaque clothing, wide-brimmed hats, and avoidance of midday sun, are recommended to minimize visible light exposure, which triggers porphyrin-mediated damage.

Emerging and novel treatments

One of the most significant advancements in acute hepatic porphyria (AHP) treatment is givosiran, an (RNAi) therapeutic approved by the (FDA) in 2019 for adults with AHP who experience recurrent attacks. Administered subcutaneously on a monthly basis, givosiran targets hepatic aminolevulinic acid synthase 1 (ALAS1) to suppress the production of neurotoxic porphyrin precursors δ-aminolevulinic acid () and porphobilinogen (PBG). In the phase 3 trial, givosiran reduced mean urinary ALA levels by 76% and PBG levels by 82% from baseline at month 6, compared to 24% and 12% with , respectively. Long-term data from open-label extensions through 2024 confirm sustained reductions exceeding 90% in ALA and PBG levels, alongside a 74% decrease in annualized attack rates among patients with (AIP). Label expansions in 2024 have broadened access for ongoing management in eligible populations. Gene therapy approaches using (AAV) vectors represent a promising curative for AIP, the most common form of AHP, by delivering a functional copy of the hydroxymethylbilane synthase (HMBS) gene to hepatocytes. Preclinical studies with AAV8 vectors have demonstrated prevention of biochemical attacks and improved neuromotor function in murine models of AIP. A phase 1 (NCT02082860) evaluating the safety of intramuscular rAAV2/5-HMBS in adults with AIP, completed in 2016, reported no serious adverse events related to the vector, though metabolic correction was limited due to delivery challenges. Updated 2024 reviews highlight ongoing phase 1/2 efforts with liver-targeted AAV vectors, showing preliminary sustained production and reduced accumulation in early trial participants without dose-limiting toxicities. These therapies aim for one-time administration to restore hepatic enzyme activity permanently. The porphyria therapeutic pipeline in 2025 includes over 10 investigational drugs across multiple modalities, addressing both hepatic and erythropoietic forms. For EPP, bitopertin, a transporter 1 (GlyT1) inhibitor, is in phase 3 development (APOLLO trial initiated mid-2025) to reduce accumulation by limiting availability for synthesis; a was submitted to the FDA in September 2025 for accelerated approval in patients aged 12 years and older with EPP or X-linked protoporphyria. Dersimelagon (MT-7117), an oral , completed phase 3 enrollment in May 2025 and aims to increase pain-free sunlight exposure by stimulating production. These candidates, developed by companies including Disc Medicine and Mitsubishi Tanabe Pharma, focus on disease-modifying mechanisms beyond symptom control. Liver transplantation remains a recent advance for severe, recurrent AIP refractory to medical therapies, offering biochemical cure by replacing the deficient hepatic HMBS . A 2021 international of 38 patients reported 1-year and 5-year survival rates of 92% and 82%, respectively, with most achieving complete resolution of attacks and improved , though neuropathy and renal impairment pre-transplant increased perioperative risks. 2024 real-world data from European centers confirm sustained attack-free survival in over 75% of cases at 5 years post-transplant, with no disease recurrence when using non-porphyric donors. (HSCT) has emerged as a curative option for recessive erythropoietic porphyrias like CEP and severe EPP, correcting the defect. In pediatric and adult cohorts, allogeneic HSCT achieves >80% long-term engraftment and normalization, with 2024 case series reporting resolution of cutaneous symptoms and in 90% of successfully engrafted patients, despite risks of .30867-5/fulltext)

Prognosis and complications

Short-term outcomes

With prompt administration of heme therapy and intravenous glucose, the majority of patients with acute porphyria attacks achieve full symptom resolution if treatment begins early. Attacks typically last 5-7 days, and the average hospital stay is 5-7 days for uncomplicated cases, though severe attacks may require longer monitoring. Complications during recovery include persistent neuropathy affecting 10-40% of patients, often manifesting as ongoing sensory or motor deficits that may take months to improve. Mortality from acute attacks has significantly declined with modern supportive care, from historically high rates to very low levels today. Favorable short-term outcomes are predicted by early and removal of precipitating triggers, such as certain medications or . Correction of , a common during attacks, is essential to prevent seizures, which can be managed with safe anticonvulsants like benzodiazepines. In cutaneous porphyrias, such as , blistering lesions on sun-exposed skin typically resolve within 2-4 weeks, though full healing may take up to several months; scarring remains permanent in affected areas.

Long-term risks

Patients with (AIP) who experience recurrent attacks without prophylactic treatment often face significant chronic symptoms, including persistent pain and fatigue that impair daily functioning. In cohorts of patients with recurrent AIP, the median number of acute attacks per year has been reported as six in the year prior to enrollment in natural history studies, with up to 8% of cases involving frequent, repeated episodes requiring ongoing management. These recurrent events contribute to long-term morbidity, such as chronic abdominal and , even in those with fewer attacks. In (PCT), there is a markedly elevated risk of (HCC), with affected individuals showing approximately a 20-fold increase compared to the general population, alongside a 7-fold higher incidence of gallbladder and cancers. Acute porphyrias are associated with and , which develop progressively and affect up to 40-60% of patients with frequent attacks, exacerbating cardiovascular and renal burdens over time. Neurological sequelae from repeated acute attacks in porphyrias can include permanent and due to axonal neuropathy, persisting between episodes and leading to reduced mobility in severe cases. Psychiatric morbidity, such as chronic depression, anxiety, and , is also common, arising from both direct neurotoxic effects and the psychological toll of recurrent illness. In severe, untreated cases historically, has been reduced by up to 10-15 years due to from complications like and renal failure, though modern management has normalized it for many. Advances in therapy, including agents like givosiran, have substantially improved outcomes by reducing annualized attack rates by about 74% in clinical trials of patients with recurrent acute hepatic porphyrias, thereby mitigating these long-term risks when combined with preventive strategies.

Epidemiology

Prevalence and distribution

Porphyrias collectively affect an estimated 10 to 20 individuals per 100,000 people , with worldwide prevalence varying by type and region, though exact figures vary due to differences in diagnostic criteria and reporting. The most prevalent type is (PCT), with a global prevalence of approximately 1 in 10,000 to 1 in 25,000 individuals, often presenting sporadically rather than strictly hereditarily. In contrast, (AIP), the most common acute form, has a symptomatic prevalence of 5 to 10 per 100,000 in and similar rates worldwide, though genetic carriers are far more common at about 1 in 2,000 in European populations. Rarer variants, such as congenital erythropoietic porphyria (CEP), occur at less than 1 per million, with approximately 200 to 250 cases documented globally. Geographic distribution shows notable variations driven by genetic founder effects and population history. (VP) is exceptionally common in , affecting 1 in 300 to 1,000 among individuals of European descent due to a shared ancestral in the PPOX gene, making it the most frequent porphyria there. Outside this region, VP prevalence drops to around 1 in 100,000 in and . Acute porphyrias like AIP exhibit higher rates in certain European populations, such as (up to 1 in 1,000 carriers), but remain low elsewhere. Underdiagnosis is prevalent in low-resource settings, where limited access to specialized biochemical and leads to overlooked cases mimicking other conditions. Prevalence trends have remained stable over recent decades, with no significant shifts in incidence reported, but detection rates are improving through widespread adoption of genetic screening programs that identify carriers and enable early intervention. These advancements, including next-generation sequencing panels targeting multiple porphyria-related genes, have enhanced diagnostic accuracy in high-income regions, potentially reducing future symptomatic cases as of 2023.

Demographic patterns

Porphyria exhibits distinct patterns across demographic groups, particularly in terms of sex, age of onset, and ethnic variations. In acute forms such as (AIP), women are 3 to 5 times more likely to experience symptomatic attacks than men, primarily due to hormonal triggers like fluctuations in sex steroids, including progesterone and , which can precipitate neurovisceral crises. In contrast, cutaneous porphyrias, such as (PCT), affect males and females equally, with no significant sex-based differences in prevalence or symptom severity. Age of onset varies markedly by porphyria subtype. Acute hepatic porphyrias typically manifest after , most commonly between 20 and 40 years of age, aligning with the period when environmental and endogenous triggers like hormonal changes become prominent. Recessive erythropoietic forms, including congenital erythropoietic porphyria (CEP) and hepatoerythropoietic porphyria (HEP), present in infancy or , often with severe from the first months of life. Ethnic and geographic factors influence the distribution of specific porphyria types. AIP shows elevated prevalence in Scandinavian populations, particularly in , where symptomatic rates reach approximately 1 in 10,000 due to founder effects and historical genetic bottlenecks. (VP) is notably more common among individuals of Dutch ancestry in , affecting about 3 in 1,000 as a result of a founder mutation introduced in the . For PCT, an acquired form, there is a strong association with (HCV) infection in Mediterranean regions, where high HCV endemicity contributes to increased incidence through hepatic uroporphyrinogen decarboxylase inhibition. Socioeconomic disparities exacerbate the burden of porphyria, particularly through delayed in underserved populations. Racial and ethnic minorities, as well as those with limited access to healthcare, often face barriers to screening and specialist referral, leading to prolonged symptom duration and higher morbidity from untreated attacks. This delay is compounded in un- and underinsured groups, where economic constraints hinder timely biochemical testing and management.

History

Early discoveries

The first documented case of what is now recognized as congenital erythropoietic porphyria (CEP), the most severe form of porphyria, was reported in 1874 by German physician Johann Schultz, who described a 33-year-old male weaver with lifelong , reddish urine, and , initially mistaking it for a form of . In 1889, Dutch physician Barend Joseph Stokvis published the initial clinical description of acute hepatic porphyria, observing dark reddish urine in a patient following ingestion of the sulphonal, marking the recognition of (AIP) as a distinct entity characterized by neurological symptoms and precursor excretion without cutaneous involvement. Early 20th-century advancements built on these observations through classification and experimental validation. In 1911, German biochemist Hans Günther systematically reviewed cases of hematoporphyria and classified porphyrias into four categories—acuta, toxica, congenita, and chronica—emphasizing their metabolic basis and linking CEP (termed congenital hematoporphyria) to inherited defects in metabolism. Swedish physician Jan Waldenström refined this in the 1930s, introducing the term "porphyria" derived from the purple-red hue of and establishing key subtypes including porphyria acuta intermittens (AIP) and (PCT), while identifying porphobilinogen (PBG) as a urinary marker in acute attacks. In 1912, German physiologist Friedrich Meyer-Betz conducted a seminal self-experiment by injecting himself with 200 mg of hematoporphyrin, subsequently experiencing severe upon sunlight exposure, which confirmed the photodynamic properties of and their role in cutaneous symptoms. Mid-20th-century research elucidated the underlying biosynthetic pathway, connecting porphyrias to enzymatic deficiencies. Following Hans Fischer's 1930 Nobel Prize-winning synthesis of and structural elucidation of porphyrins, post-1945 studies by David Shemin and others mapped the eight-step pathway from and to , identifying delta-aminolevulinic acid (ALA) as the initial precursor in 1953, and revealing regulation by in 1963, which explained precursor accumulation in porphyrias. This biochemical framework enabled the first : in 1971, intravenous was administered to a terminally ill AIP patient at the , rapidly alleviating symptoms by repressing hepatic ALA synthase activity and reducing porphyrin precursor overproduction, establishing hemin as the cornerstone for acute attack management. Genetic milestones in the and solidified the molecular basis of porphyrias. The hydroxymethylbilane synthase (HMBS) gene, deficient in AIP, was cloned in 1987 by Grandchamp et al., allowing identification of over 400 mutations and confirming autosomal dominant inheritance with low . By the early , mutations in all eight synthesis genes had been characterized, leading to a modern classification of eight distinct porphyrias—four acute hepatic forms ( [AIP], [VP], hereditary coproporphyria [HCP], and ALA dehydratase deficiency porphyria [ADP]) and four mainly cutaneous forms ( [PCT], congenital erythropoietic porphyria [CEP], [EPP], and hepatoerythropoietic porphyria [HEP])—based on specific enzyme defects, organ involvement, and clinical manifestations.

Cultural and literary impacts

Porphyria has left a notable mark on historical narratives, particularly through speculations linking the disease to the mental instability of prominent figures. The most enduring association is with King George III of , whose recurrent episodes of and physical symptoms—such as , discolored urine, and neurological disturbances—were attributed to or by psychiatrists Ida Macalpine and Richard Hunter in 1966. This theory, based on reinterpretations of 18th- and 19th-century medical records including those from physicians like Francis Willis, suggested that the king's condition contributed to key events like the loss of the American colonies during his reign. However, subsequent research has challenged this diagnosis, highlighting selective evidence use by Macalpine and Hunter, inconsistencies in urine color reports, and stronger alignment with , as evidenced by detailed episode reviews identifying four to five manic phases. Despite these critiques, the porphyria hypothesis persists in popular historiography, influencing perceptions of the Hanoverian dynasty and underscoring how rare diseases can reshape interpretations of political history. Speculation extends to other royals, though evidence remains anecdotal and unverified. (1542–1587), George III's ancestor, is thought by some to have exhibited symptoms consistent with , including intermittent abdominal crises and psychological episodes, potentially inherited through the Stuart line to James I (1566–1625), who reportedly suffered similar urinary and neurological issues. These claims, first systematically proposed in the , illustrate porphyria's role in "" trends, where modern medical knowledge is applied to historical records, often amplifying the disease's mystique in biographical literature. In folklore and literature, porphyria's cutaneous forms, particularly porphyria cutanea tarda and congenital erythropoietic porphyria, have been popularly connected to myths originating in . Symptoms such as extreme causing blistering and scarring upon sun exposure, pale or reddish skin, receding gums that expose teeth (mimicking fangs), and align with traits like sunlight aversion and nocturnal habits, while the need for supplementation—though not —has been exaggerated into blood-drinking lore. This linkage gained traction in the through and media, with Transylvanian genetic isolates potentially fueling 18th-century vampire panics reported in Western newspapers. However, experts describe this as sensationalized, noting porphyria's rarity and its overlap with other conditions like or in shaping the myth, rather than being its sole origin. The association permeates gothic , implicitly referenced in Bram Stoker's Dracula (1897) through the protagonist's aversion to daylight and (a traditional porphyria remedy), and endures in modern as the "vampire disease," appearing in films, TV series, and awareness campaigns by organizations like the American Porphyria Foundation.

References

  1. https://www.mayoclinic.org/diseases-conditions/porphyria/symptoms-causes/syc-20356066
  2. https://www.niddk.nih.gov/health-information/liver-disease/porphyria
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC5916231/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC9885782/
  5. https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2024.1374965/full
  6. https://medlineplus.gov/genetics/condition/porphyria/
  7. https://emedicine.medscape.com/article/1389981-overview
  8. https://porphyriafoundation.org/for-patients/types-of-porphyria/
  9. https://www.ncbi.nlm.nih.gov/books/NBK100826/
  10. https://www.ncbi.nlm.nih.gov/books/NBK537329/
  11. https://onlinelibrary.wiley.com/doi/full/10.1111/liv.15965
  12. https://journals.asm.org/doi/10.1128/mmbr.00048-16
  13. https://www.ncbi.nlm.nih.gov/books/NBK537352/
  14. https://www.ncbi.nlm.nih.gov/books/NBK1193/
  15. https://www.ncbi.nlm.nih.gov/books/NBK547665/
  16. https://www.ncbi.nlm.nih.gov/books/NBK563209/
  17. https://emedicine.medscape.com/article/1103643-overview
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC5664971/
  19. https://rarediseases.info.nih.gov/diseases/7433/porphyria-cutanea-tarda
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC9857840/
  21. https://www.ncbi.nlm.nih.gov/books/NBK154652/
  22. https://www.ncbi.nlm.nih.gov/books/NBK143129/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6542720/
  24. https://www.genome.gov/Genetic-Disorders/Porphyria
  25. https://porphyriafoundation.org/for-patients/about-porphyria/genetics/
  26. https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V22.4.202544/537938/Not-So-BenignAcute-Hepatic-Porphyria-Rare
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC7586877/
  28. https://porphyriafoundation.org/for-patients/types-of-porphyria/pct/
  29. https://ghr.nlm.nih.gov/condition/porphyria
  30. https://emedicine.medscape.com/article/957604-overview
  31. https://porphyriafoundation.org/for-patients/types-of-porphyria/aip/
  32. https://ashpublications.org/blood/article/142/19/1589/495267/RNA-interference-therapy-in-acute-hepatic
  33. https://porphyriafoundation.org/drugdatabase/
  34. https://porphyriafoundation.org/for-healthcare-professionals/drug-safety1/
  35. https://ojrd.biomedcentral.com/articles/10.1186/s13023-022-02314-9
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4640448/
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC7252266/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC8700611/
  39. https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2021.715523/full
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC6448269/
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC1028543/
  42. https://pubmed.ncbi.nlm.nih.gov/9092747/
  43. https://pubmed.ncbi.nlm.nih.gov/31142411/
  44. https://now.aapmr.org/porphyria/
  45. https://arupconsult.com/content/porphyrias
  46. https://www.sciencedirect.com/science/article/pii/S0002962921000938
  47. https://testdirectory.questdiagnostics.com/test/test-guides/TG_Porphyria/porphyria-laboratory-evaluation
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC11815605/
  49. https://porphyriafoundation.org/for-patients/about-porphyria/testing-for-porphyria/dna-testing-for-porphyria/
  50. https://genetics.testcatalog.org/show/PCGP
  51. https://ashpublications.org/hematology/article/2020/1/400/474288/Updates-on-the-diagnosis-and-management-of-the
  52. https://porphyrianet.org/en/content/laboratory-working-group-wg-la
  53. https://www.gastrojournal.org/article/S0016-5085(22)01356-7/fulltext
  54. https://porphyriafoundation.org/for-healthcare-professionals/emergency-room-guidelines-for-acute-porphyrias/
  55. https://www.rareconnect.org/uploads/documents/best-practice-guidelines.pdf
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC4562648/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC11665593/
  58. https://rarediseases.org/rare-diseases/acute-intermittent-porphyria/
  59. https://www.drugs-porphyria.org/
  60. https://www.sciencedirect.com/science/article/pii/S1096719218305286
  61. https://my.clevelandclinic.org/health/diseases/24112-acute-hepatic-porphyria
  62. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.712305/full
  63. https://gastro.org/clinical-guidance/diagnosis-and-management-of-acute-hepatic-porphyrias-ahp/
  64. https://www.porphyria.org/research-opportunities/elevate
  65. https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.29231
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC11665602/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC3501544/
  68. https://pubmed.ncbi.nlm.nih.gov/22985607/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC4780255/
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC5161401/
  71. https://www.ncbi.nlm.nih.gov/books/NBK563141/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC9968824/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC3214312/
  74. https://www.ncbi.nlm.nih.gov/omim/263700
  75. https://pmc.ncbi.nlm.nih.gov/articles/PMC4966423/
  76. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-givosiran-acute-hepatic-porphyria
  77. https://www.alnylam.com/sites/default/files/pdfs/GIVLAARI-Prescribing-Information.pdf
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC2839207/
  79. https://clinicaltrials.gov/study/NCT02082860
  80. https://onlinelibrary.wiley.com/doi/10.1111/liv.15979
  81. https://www.openpr.com/news/4194845/porphyria-pipeline-2025-key-clinical-innovations-from-over-10
  82. https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-announces-submission-new-drug-application-nda-us
  83. https://www.mt-pharma-america.com/media/press-releases/2025/mitsubishi-tanabe-pharma-america-announces-completion-of-enrollment-for-its-phase-3-inspire-study-of-investigational-dersimelagon-in-patients-with-epp-and-xlp
  84. https://pubmed.ncbi.nlm.nih.gov/33259654/
  85. https://journals.lww.com/lt/fulltext/2021/04000/liver_transplantation_for_acute_intermittent.10.aspx
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC11594983/
  87. https://pmc.ncbi.nlm.nih.gov/articles/PMC11670562/
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC6132435/
  89. https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-025-04064-0
  90. https://www.sciencedirect.com/science/article/pii/S2214426922000027
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC7575966/
  92. https://www.researchgate.net/publication/11918630_The_management_of_porphyria_cutanea_tarda
  93. https://journals.lww.com/hep/fulltext/2020/05000/explore__a_prospective%2C_multinational%2C_natural.8.aspx
  94. https://onlinelibrary.wiley.com/doi/full/10.1111/liv.15966
  95. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/the-porphyrias/acute-porphyrias
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC8613433/
  97. https://www.mdpi.com/2075-1729/12/12/2059
  98. https://www.molinamarketplace.com/marketplace/id/en-us/Providers/-/media/292346C4EEAA470B952B64CB9097D4B9.ashx
  99. https://www.niddk.nih.gov/health-information/liver-disease/porphyria/
  100. https://rarediseases.org/rare-diseases/congenital-erythropoietic-porphyria/
  101. https://rarediseases.org/rare-diseases/variegate-porphyria/
  102. https://pubmed.ncbi.nlm.nih.gov/23114748/
  103. https://new.porphyrianet.org/en/content/porphyrias
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC3583083/
  105. https://www.thebloodproject.com/wp-content/uploads/2022/07/Porphyria_4.pdf
  106. https://www.sciencedirect.com/science/article/abs/pii/S1521691810000818
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC4563803/
  108. https://porphyriafoundation.org/for-patients/types-of-porphyria/hep/
  109. https://pubmed.ncbi.nlm.nih.gov/12372055/
  110. https://porphyriafoundation.org/for-patients/types-of-porphyria/vp/
  111. https://pubmed.ncbi.nlm.nih.gov/31097365/
  112. https://medicaljournalssweden.se/actadv/article/download/11255/15012
  113. https://bwhi.org/2021/04/14/acute-hepatic-porphyria-learn-about-a-rare-disease-that-disproportionately-affects-women/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC11661304/
  115. https://pmc.ncbi.nlm.nih.gov/articles/PMC1852202/
  116. https://onlinelibrary.wiley.com/doi/full/10.1111/liv.15960
  117. https://www.jbc.org/article/S0021-9258(19)77941-0/fulltext
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC4542079/
  119. https://porphyriafoundation.org/for-patients/about-porphyria/history-of-porphyria/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC4953321/
  121. https://www.pbs.org/newshour/health/what-illness-did-king-george-iii-have
  122. https://www.nytimes.com/1969/07/03/archives/2-britons-find-royalty-plagued-by-metabolic-disorder-history-of.html
  123. https://pubmed.ncbi.nlm.nih.gov/21902081/
  124. https://www.bbc.com/future/article/20161031-the-real-life-disease-that-spread-the-vampire-myth
  125. https://jamanetwork.com/journals/jamadermatology/fullarticle/2547233
  126. https://www.visiblebody.com/blog/3-real-diseases-that-influenced-vampire-folklore
Add your contribution
Related Hubs
User Avatar
No comments yet.